Mary Heino Biography and Net Worth

CEO of Lantheus

Mary Anne Heino brings to Lantheus 30 years of diverse pharmaceutical industry experience. Joining Lantheus in April 2013 as Chief Commercial Officer, Ms. Heino was promoted to Chief Operating Officer in March 2015 and to President and Chief Executive Officer in August 2015. Prior to joining Lantheus, Ms. Heino led Angelini Labopharm LLC and Labopharm USA in the roles of President and Senior Vice President of World Wide Sales and Marketing. Before that, Ms. Heino served in numerous capacities at Centocor, Inc., a Johnson & Johnson Company, including Vice President Strategic Planning and Competitive Intelligence, Vice President Sales, Executive Director Customer Relationship Management and Senior Director Immunology Marketing. Ms. Heino began her professional career with Janssen Pharmaceutica N.V. as a Sales Representative in June 1989 and worked her way up to the role of Field Sales Director in 1999. Ms. Heino received her Master’s in Business Administration from the Stern School of Business at New York University. She earned a Bachelor’s of Science in Nursing from the City University of New York and a Bachelor’s of Science in Biology from the State University of New York at Stony Brook. She is currently on the Board of Directors for MassMEDIC, an industry association that serves the MedTech community of Massachusetts, and serves on the Executive Committee for the Massachusetts Business Roundtable (MBR).

What is Mary Anne Heino's net worth?: The estimated net worth of Mary Anne Heino is at least $3.71 million as of June 7th, 2024. Ms. Heino owns 37,719 shares of Lantheus stock worth more than $3,714,605 as of April 10th. This net worth evaluation does not reflect any other investments that Ms. Heino may own. Learn More about Mary Anne Heino's net worth.
How do I contact Mary Anne Heino?: The corporate mailing address for Ms. Heino and other Lantheus executives is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. Lantheus can also be reached via phone at (978) 671-8001 and via email at ir@lantheus.com. Learn More on Mary Anne Heino's contact information.
Has Mary Anne Heino been buying or selling shares of Lantheus?: Mary Anne Heino has not been actively trading shares of Lantheus in the last ninety days. Most recently, Mary Anne Heino sold 2 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $100.13, for a transaction totalling $200.26. Following the completion of the sale, the director now directly owns 8,618 shares of the company's stock, valued at $862,920.34. Learn More on Mary Anne Heino's trading history.
Who are Lantheus' active insiders?: Lantheus' insider roster includes Minnie Baylor-Henry (Director), Gerard Ber (Director), Paul Blanchfield (Insider), John Bolla (COO), Michael Duffy (SVP), Mary Heino (CEO), Sam Leno (Director), Heinz Maeusli (Director), Brian Markison (CEO & Director), Robert Marshall, Jr. (CFO), Etienne Montagut (Insider), Daniel Niedzwiecki (Insider), Gary Pruden (Director), Andrea Sabens (CAO), James Thrall (Director), and Carol Walker (SVP). Learn More on Lantheus' active insiders.
Are insiders buying or selling shares of Lantheus?: During the last year, insiders at the medical equipment provider sold shares 15 times. They sold a total of 137,231 shares worth more than $12,590,187.37. The most recent insider tranaction occured on March, 17th when CFO Robert J Jr. Marshall sold 10,000 shares worth more than $1,005,200.00. Insiders at Lantheus own 1.5% of the company. Learn More about insider trades at Lantheus.
Information on this page was last updated on 3/17/2025.

Mary Anne Heino Insider Trading History at Lantheus

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/13/2025	Sell	2	$100.13	$200.26	8,618
3/3/2025	Sell	53,107	$94.35	$5,010,645.45	440,399
8/2/2024	Sell	10,481	$95.50	$1,000,935.50	454,923
6/7/2024	Sell	1	$81.26	$81.26	37,719
3/4/2024	Sell	93,863	$65.31	$6,130,192.53	251,643
11/13/2023	Sell	11,780	$63.72	$750,621.60	317,687
8/11/2023	Sell	10,950	$68.58	$750,951.00	329,467
3/27/2023	Sell	44,484	$80.77	$3,592,972.68	419,397
3/8/2023	Sell	10,064	$74.70	$751,780.80	719,397
3/6/2023	Sell	12,189	$73.24	$892,722.36	729,461
3/3/2023	Sell	82,055	$73.00	$5,990,015.00	741,650
11/8/2022	Sell	13,150	$57.21	$752,311.50	672,533
5/9/2022	Sell	12,276	$61.19	$751,168.44	695,115
3/3/2022	Sell	11,173	$52.13	$582,448.49
2/28/2022	Sell	43,909	$46.50	$2,041,768.50
11/10/2021	Sell	13,333	$30.12	$401,589.96
4/12/2021	Sell	19,421	$20.66	$401,237.86
3/5/2021	Sell	27,157	$18.26	$495,886.82	711,720
7/23/2020	Sell	3,000	$16.02	$48,060.00	604,793
7/15/2020	Sell	22,125	$16.01	$354,221.25	607,793
4/27/2020	Sell	30,033	$13.77	$413,554.41	634,318
2/26/2020	Sell	6,615	$17.09	$113,050.35	549,399
2/24/2020	Sell	9,898	$16.06	$158,961.88	556,014
12/20/2019	Sell	19,260	$20.85	$401,571.00	563,034
9/20/2019	Sell	15,590	$25.81	$402,377.90	582,294
9/3/2019	Sell	25,538	$21.21	$541,660.98	597,884
6/20/2019	Sell	14,340	$27.89	$399,942.60	624,997
5/20/2019	Sell	16,827	$23.89	$401,997.03	637,762
4/26/2019	Sell	29,813	$24.86	$741,151.18	654,589
4/12/2019	Sell	15,799	$25.40	$401,294.60	684,402
3/5/2019	Sell	9,294	$23.35	$217,014.90	709,220
2/25/2019	Sell	9,456	$24.06	$227,511.36	621,326
1/30/2019	Sell	9,564	$16.47	$157,519.08	630,782
7/12/2017	Sell	10,000	$18.05	$180,500.00	592,468
6/12/2017	Sell	10,000	$15.39	$153,900.00	602,468

See Full Table

Mary Anne Heino Buying and Selling Activity at Lantheus

Lantheus Company Overview

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Today's Range

Now: $98.48

$93.88

$99.59

50 Day Range

MA: $93.62

$78.23

$110.01

2 Week Range

Now: $98.48

$58.46

$126.89

Volume

953,982 shs

Average Volume

953,034 shs

Market Capitalization

$6.74 billion

P/E Ratio

16.39

Dividend Yield

N/A

Beta

0.2